AUS
NZ
UK
CA
USA
IND
Bodycote plc (BOY), the global leader in thermal processing services, released its interim results for the first half of 2026, reporting an adjusted operating profit of a361.0m, marking a 10.7% increase year-over-year, alongside core organic revenue growth of 9.6%. Despite ongoing geopolitical and macroeconomic challenges, the company upheld its full-year guidance, driven by robust demand in aerospace and defence sectors, offsetting persistent difficulties in European automotive markets.
Key Highlights
- Bodycote plc (BOY) operates as the world e2 80 99s largest thermal processing services provider, with Specialist Technologies and Precision Heat Treatment divisions across 22 countries.
- In H1 2026, core organic revenue rose 9.6%, adjusted operating profit climbed 10.7% to a361.0m, and adjusted basic earnings per share increased 18.3% to 25.2p.
- Aerospace & Defence revenue surged 25% organically, propelled by commercial aerospace, defence, and space programs; Industrial Gas Turbine revenue linked to semiconductors grew 11%, partially offset by a 4% decline in automotive.
- The Optimise programme contributed approximately a31m in profit improvements during H1, completing 27 of 31 planned plant closures, disposals, and consolidations; expansion of the programme is under consideration.
- Investors should closely watch H2 2026 performance amid moderating growth comparisons and ongoing macroeconomic headwinds, as well as progress on organic investment projects launching in 2027.
Robust Core Organic Growth Driven by Aerospace and Industrial Gas Turbine Sectors
Bodycote achieved 9.6% core organic revenue growth in H1 2026, significantly outperforming the total group growth of 3.3%. Core revenues reached a3372.0m (H1 2025: a3336.6m), mainly fueled by a 25% organic increase in aerospace and defence revenue, benefiting from high-growth commercial aerospace programs like the LEAP engine and strong defence and space sector demand. This marked a turnaround from H1 2025, which faced supply chain disruptions in commercial aerospace.
Beyond aerospace, Industrial Gas Turbine revenue rose 11% organically, supported by data center expansion demand, while combined medical and semiconductor segments grew 15%. Specialist Technologies, heavily exposed to these markets, posted remarkable 16.7% organic revenue growth, reversing a negative 8% prior-year figure, now representing 50% of division revenue due to market share gains and contract renewals. However, Western European automotive markets continued to decline by 4%, a structural challenge expected to persist.
Margin Growth Despite Normalising Variable Pay and Investment Pressures
Core adjusted operating margins expanded by 30 basis points to 16.2% in H1 2026, despite headwinds from normalising variable remuneration and ramp-up costs for growth initiatives. The Optimise programme contributed around a31m in profit improvements, aiding margin expansion through revenue leverage.
On a group-wide basis, including non-core operations, adjusted operating margins increased by 110 basis points to 16.0%, reflecting portfolio improvements and a 71.6% reduction in non-core revenue to a39.2m (H1 2025: a332.4m) due to plant closures and disposals. Non-core operations, with lower margins of 6.5%, are diminishing as a drag on profitability. Precision Heat Treatment margins remained stable at 15.0%, balancing growth benefits against lower margins from transferred non-core revenue and variable pay impacts. Statutory operating profit rose 10.7% to a345.6m, with Optimise-related exceptional charges totaling a310.4m (H1 2025: a39.1m).
Specialist Technologies Capitalises on Aerospace Sector Growth
Specialist Technologies revenue increased to a3121.2m in H1 2026 (H1 2025: a3104.5m), reflecting 16.7% organic growth driven by aerospace and defence, now comprising 50% of division revenue. The division secured two major long-term agreement renewals during H1, enhancing revenue visibility and market share.
Adjusted operating profit rose 16.2% to a331.6m, with margins stable at 26.1%. Temporary ramp-up costs and a higher proportion of surface technology work with elevated raw material pass-through costs tempered operational leverage. Despite favorable prior-year comparators due to supply chain issues, management affirms genuine underlying momentum driven by structural aerospace and defence demand.
Precision Heat Treatment Encounters Automotive Challenges Amid Aerospace Gains
Precision Heat Treatment generated a3250.8m revenue in H1 2026 (H1 2025: a3232.1m), a 6.4% organic increase supported by aerospace and defence (+16%), energy (+9%), and consumer, medical, and other segments (+14%), offset by a 4% decline in automotive due to structural issues in Western Europe. Industrial markets grew modestly by 4%, including revenue transferred from non-core sites under the Optimise programme, initially at lower margins.
Adjusted operating profit increased 7.7% to a337.6m, while margins remained flat at 15.0%, reflecting the balance of growth, higher variable pay, and lower-margin transferred revenue. Management expects margin improvements in H2 2026 and 2027 as transferred volumes scale and ramp-up costs normalize.
Optimise Programme Advances; Potential Expansion Under Review
The Optimise programme progressed with 27 of 31 planned plant closures, disposals, and consolidations completed in H1 2026, delivering approximately a31m in profit improvements and significantly enhancing portfolio quality by eliminating low-margin operations. Non-core revenue dropped 71.6%, including the November 2025 sale of ten automotive and industrial sites in France.
Bodycote is evaluating expanding the Optimise programme to target additional sites in challenging automotive and industrial markets, though no final decisions have been made. Exceptional charges related to the programme totaled a310.4m in H1 2026 (H1 2025: a39.1m), covering closure costs, severance, impairments, and related expenses, with further charges expected in H2 2026.
Spectrum Acquisition Successfully Integrated; M&A Pipeline Growing
In January 2026, Bodycote acquired Spectrum Thermal Processing LLC for approximately a36m, enhancing aerospace and defence capabilities in North America. Spectrum has integrated smoothly and performed strongly in H1 2026, aligning with management expectations.
Bodycote is advancing a significant M&A pipeline focused on Specialist Technologies and strategic markets to enhance portfolio quality and growth. The company maintains a conservative leverage of approximately 0.7x net debt to EBITDA, with net debt excluding leases at a3135.2m and a3127.4m liquidity available under a a3251m revolving credit facility maturing in September 2030, supporting selective value-accretive acquisitions.
Capital Expenditure Supports Greenfield and Capacity Expansion Initiatives
Net capital expenditure totaled a333.5m in H1 2026 (H1 2025: a338.0m), reflecting phasing of major projects with expected acceleration in H2. Investments include greenfield sites in South Korea and Mexico set to open in 2027, high isostatic pressure capacity expansions in Europe and North America, and major upgrades to two Precision Heat Treatment aerospace and defence sites in North America.
Management highlighted that these organic investments will cause temporary P&L headwinds in 2026 due to ramp-up and commissioning costs, with revenue and profit contributions anticipated to grow through 2027. Shareholder returns included approximately a345m in H1 via dividends ( a327.5m) and share buybacks ( a317.8m), acquiring 1.9m shares at an average price near 680p under an a380m buyback programme.
Earnings Per Share Growth Outpaces Profit Due to Share Buybacks
Adjusted basic earnings per share rose 18.3% to 25.2p in H1 2026 (H1 2025: 21.3p), surpassing the 10.7% adjusted operating profit increase, reflecting the impact of share buybacks. Statutory basic EPS increased 16.8% to 18.1p (H1 2025: 15.5p). The a380m share buyback programme launched in March 2026 contributed to these per-share gains.
The divergence between profit and EPS growth underscores the effect of share repurchases on per-share metrics, while the 10.7% profit growth more accurately represents business momentum. The company e2 80 99s capital allocation balanced organic investment ( a333.5m), acquisitions (c. a36m), dividends ( a327.5m), and buybacks ( a317.8m), totaling about a384m, reflecting confidence in cash flow and strategic flexibility.
Full-Year 2026 Guidance Unchanged Amid Economic Uncertainty
Bodycote reaffirmed its full-year 2026 guidance, mindful of geopolitical and macroeconomic uncertainties. The company anticipates core organic revenue growth driven by aerospace, defence, and industrial gas turbines, partially offset by automotive sector challenges. Growth is expected to moderate in H2 2026 due to tougher prior-year comparisons, especially in aerospace and defence.
Operating margins are projected to improve, supported by revenue growth and Optimise programme benefits, though offset by normalising variable pay and ramp-up costs for new initiatives. Management remains confident in meeting medium-term targets and sustaining performance into 2027 and beyond.
Stable Cash Generation; Working Capital Reflects Revenue Expansion
Adjusted operating cash flow rose 10.3% to a341.6m in H1 2026 (H1 2025: a337.7m), maintaining a consistent 68% cash conversion rate. Free cash flow declined slightly to a314.5m (H1 2025: a318.0m) due to increased restructuring costs ( a39.5m vs. a37.0m) and higher cash tax payments ( a313.6m vs. a38.7m), with elevated tax phasing expected throughout 2026.
Working capital outflow increased to a312.6m (H1 2025: a37.6m), driven by higher receivables from revenue growth and seasonal factors. Closing net debt excluding lease liabilities stood at a3135.2m as of 30 June 2026, up from a3104.8m at year-end 2025, reflecting shareholder returns, acquisition costs, and restructuring spend. The conservative leverage ratio of 0.7x net debt to EBITDA supports financial flexibility for growth and acquisitions.
This article is for informational purposes only and does not constitute investment advice. The details are based solely on Bodycote plc's interim results announcement and should not be interpreted as a recommendation to buy, sell, or hold company shares. Investors are advised to perform their own analysis and consult qualified financial professionals before making investment decisions. Past performance does not guarantee future results, and investments carry risks including potential capital loss. Forward-looking statements involve risks and uncertainties that could cause actual outcomes to differ materially.
